Want to see HK:3759 full AI Analyst Report?
Top Page
Pharmaron Beijing Co., Ltd. Class H
(3759)
Select Model
Select Model
Rating:53Neutral
Price Target:
HK$27.00
â–˛(11.85% Upside)
Action:Reiterated
Date:10/29/26
The score is held back primarily by weakening cash-flow quality (negative TTM free cash flow) alongside margin compression and rising debt risk, despite strong revenue growth and still-positive profitability. Technical indicators also show weak near-term momentum (below 20/50-DMAs and negative MACD). Valuation further pressures the score due to a high P/E and a low dividend yield.
Positive Factors
Strong Revenue Growth
Sustained revenue expansion indicates continued demand for the company’s research, development, and manufacturing services. Robust TTM growth provides a durable foundation for scaling operations, supporting reinvestment, and preserving the company’s relevance across the pharmaceutical and biotechnology development cycle.
Negative Factors
Margin Compression
The decline in net margin from roughly 22% to 11% shows that revenue growth is producing less profit per unit of sales than in earlier years. If this normalization persists, it could limit earnings growth, reduce reinvestment capacity, and weaken the long-term operating leverage of the business.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Sustained revenue expansion indicates continued demand for the company’s research, development, and manufacturing services. Robust TTM growth provides a durable foundation for scaling operations, supporting reinvestment, and preserving the company’s relevance across the pharmaceutical and biotechnology development cycle.
Read all positive factors
Pharmaron Beijing Co., Ltd. Class H (3759) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$77.36B
Dividend Yield0.85%
Average Volume (3M)5.39M
Price to Earnings (P/E)40.8
Beta (1Y)1.48
Revenue Growth24.21%
EPS Growth19.72%
CountryHK
Employees25,088
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.99
Shares Outstanding359,977,870
10 Day Avg. Volume5,873,049
30 Day Avg. Volume5,385,747
Financial Highlights & Ratios
PEG Ratio-2.70
Price to Book (P/B)2.06
Price to Sales (P/S)2.20
P/FCF Ratio56.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$42.72Price Target Upside76.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.27
Revenue Forecast (FY)HK$19.50B
Pharmaron Beijing Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laborat...
Pharmaron Beijing Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
67
Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.90B | 14.10B | 12.28B | 11.54B | 10.27B | 7.44B |
| Gross Profit | 5.32B | 4.91B | 4.20B | 4.12B | 3.77B | 2.68B |
| EBITDA | 2.65B | 3.29B | 3.38B | 2.95B | 2.53B | 2.49B |
| Net Income | 1.77B | 1.66B | 1.79B | 1.60B | 1.37B | 1.66B |
Balance Sheet | ||||||
| Total Assets | 32.22B | 27.09B | 23.93B | 26.48B | 20.49B | 18.39B |
| Cash, Cash Equivalents and Short-Term Investments | 4.03B | 1.73B | 2.81B | 6.72B | 2.24B | 5.10B |
| Total Debt | 7.46B | 3.42B | 5.54B | 9.36B | 6.12B | 5.29B |
| Total Liabilities | 14.64B | 11.36B | 9.70B | 13.24B | 9.65B | 8.09B |
| Stockholders Equity | 16.88B | 15.06B | 13.62B | 12.56B | 10.55B | 10.13B |
Cash Flow | ||||||
| Free Cash Flow | -242.61M | 551.97M | 536.02M | -111.78M | -807.04M | -34.78M |
| Operating Cash Flow | 2.75B | 3.22B | 2.58B | 2.75B | 2.14B | 2.06B |
| Investing Cash Flow | -4.81B | -4.37B | -2.02B | -2.25B | -2.21B | -5.26B |
| Financing Cash Flow | 3.66B | 377.00M | -4.80B | 3.92B | -1.42B | 3.66B |
Pharmaron Beijing Co., Ltd. Class H Technical Analysis
Neutral
24.14
Price Trends
29.56
Negative
25.41
Positive
22.66
Positive
Market Momentum
-0.84
Positive
41.68
Neutral
47.98
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3759, the sentiment is Neutral. The current price of 24.14 is below the 20-day moving average (MA) of 28.99, below the 50-day MA of 29.56, and above the 200-day MA of 22.66, indicating a neutral trend. The MACD of -0.84 indicates Positive momentum. The RSI at 41.68 is Neutral, neither overbought nor oversold. The STOCH value of 47.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:3759.
Pharmaron Beijing Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$190.69B | 32.52 | 10.51% | ― | 21.93% | 21.94% | |
64 Neutral | HK$83.40B | -15.67 | -16.23% | 0.35% | 53.48% | -120.02% | |
64 Neutral | HK$2.79B | 13.87 | 4.45% | 0.27% | 7.38% | 7.90% | |
63 Neutral | HK$3.04B | 36.53 | 3.02% | ― | 10.32% | 178.23% | |
58 Neutral | HK$55.56B | 41.29 | 6.66% | 1.37% | 23.95% | 18.73% | |
53 Neutral | HK$77.36B | 40.82 | 10.93% | 0.85% | 24.21% | 19.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:3759
Pharmaron Beijing Co., Ltd. Class H
26.92
1.78
7.10%
HK:1548
Genscript Biotech
37.70
21.52
133.00%
HK:2269
Wuxi Biologics (Cayman)
45.06
8.48
23.18%
HK:1521
Frontage Holdings Corp.
1.49
0.24
19.20%
HK:1873
Viva Biotech Holdings
1.28
-1.09
-45.97%
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
105.10
20.47
24.19%
Pharmaron Beijing Co., Ltd. Class H Corporate Events
Pharmaron Beijing Issues Unaudited 2026 Third-Quarter Report Under PRC and IFRS Standards
Oct 27, 2026
Pharmaron Beijing Co., Ltd. has released its unaudited third quarterly report for 2026, prepared mainly under PRC Accounting Standards for Business Enterprises, with certain sections based on International Financial Reporting Standards. The announ...
Pharmaron Renews Connected Research Framework with Newbay Technology
Oct 27, 2026
Pharmaron Beijing Co., Ltd., a China-based pharmaceutical contract research and manufacturing service provider, offers integrated research, development, manufacturing and clinical technical services to biopharma clients, including commissioned exp...
Pharmaron’s Major Shareholder Sells 1% Stake in A Share Placement
Oct 15, 2026
Pharmaron Beijing Co., Ltd. disclosed that its substantial shareholder, Pharmaron Holdings Limited, has disposed of 18,373,000 A shares, equal to about 1.00% of the company’s total issued share capital. The shares were transferred via an inq...
Pharmaron Schedules Board Meeting to Approve Third-Quarter Results
Oct 13, 2026
Pharmaron Beijing Co., Ltd. has scheduled a meeting of its board of directors for October 27, 2026, to review and approve the third quarterly results for the nine months ended September 30, 2026, and to authorize their publication. The announcemen...
Pharmaron Grants Over 2 Million H Share Awards Under 2025 Incentive Scheme
Sep 18, 2026
Pharmaron Beijing Co., Ltd. has granted 2,042,159 H share awards at no consideration to 221 eligible employees under its 2025 H Share Award and Trust Scheme, with none of the grantees being directors, chief executives or substantial shareholders. ...
Pharmaron Shareholders Approve 2026 Meetings Resolutions and Governance Amendments
Sep 10, 2026
Pharmaron Beijing Co., Ltd. announced that its First Extraordinary General Meeting of 2026, along with separate A Share and H Share class meetings, were duly convened in Beijing on 10 September 2026 and all resolutions were approved by poll. The m...
Pharmaron Completes US$330 Million Convertible Bond Issue to Fund Expansion
Sep 2, 2026
Pharmaron Beijing Co., Ltd. has completed the issuance of RMB2.18 billion in USD-settled zero coupon convertible bonds due 2027 under its general mandate, with the closing occurring on September 2, 2026. The bonds are convertible into H shares at ...
Pharmaron Beijing to Raise US$330 Million via Premium-Priced Convertible Bonds
Aug 26, 2026
Pharmaron Beijing plans to issue RMB2,180 million worth of USD-settled zero coupon convertible bonds due 2027 under its general mandate, following a book-building process that has set key terms. The bonds will be subscribed by a manager who may pr...
Pharmaron Beijing Calls 2026 H Share Class Meeting to Seek Repurchase Mandate
Aug 25, 2026
Pharmaron Beijing Co., Ltd. has called its first H share class meeting of 2026 for September 10 in Beijing, immediately following its extraordinary general meeting and A share class meeting. The session will ask H shareholders to consider and appr...
Pharmaron Beijing Calls 2026 EGM to Approve Incentive, Buyback and Offshore Debt Plans
Aug 25, 2026
Pharmaron Beijing Co., Ltd. has convened its first extraordinary general meeting of 2026 for September 10 in Beijing, inviting H shareholders of record as of September 7 to attend and vote. The meeting notice details procedures for share registrat...
Pharmaron Sets H Share Register Closure for 2026 Extraordinary Meetings
Aug 21, 2026
Pharmaron Beijing Co., Ltd. has announced administrative arrangements for its H shareholders ahead of the First Extraordinary General Meeting of 2026 and the First H Share Class Meeting of 2026, both scheduled for the afternoon of 10 September 202...
Pharmaron Beijing Posts Solid H1 2026 Growth But Holds Interim Dividend
Aug 20, 2026
Pharmaron Beijing Co., Ltd. reported interim results for the six months ended June 30, 2026, showing revenue of RMB7.60 billion, up 17.9% year-on-year, and profit attributable to owners of the parent rising 7.0% to RMB750.2 million. Non-IFRS adjus...
Pharmaron Reshapes Segment Reporting to Highlight Integrated Multi‑Modality R&D Platform
Aug 20, 2026
Pharmaron Beijing Co., Ltd. has reorganized its business and adjusted its segment reporting to better reflect its integrated pharmaceutical RD services platform. The company is consolidating its offerings into three core segments—laboratory ...
Pharmaron Schedules Board Meeting to Approve 2026 Interim Results
Aug 6, 2026
Pharmaron Beijing Co., Ltd. has scheduled a board meeting for August 20, 2026, to review and approve the interim results for the six months ended June 30, 2026, and to consider their publication. The announcement signals the company’s prepar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.